药品专利强制许可制度在发展中国家的应用——从“抗癌药代购第一人”陆勇事件谈起  

The Application of Compulsory Licensing of Medicine Patent in Developing Countries:From the Perspective of “Lu Yong” Case

作　　者：郝敏[1] 

机构地区：[1]国际关系学院

出　　处：《知识产权》2015年第8期95-101,共7页Intellectual Property

摘　　要："抗癌药代购第一人"陆勇事件引发社会各界的广泛关注,该事件不只涉及刑法问题,其背后透露出的发展中国家完善和实施药品专利强制许可的必要性和紧迫性更值得学界深思。以印度作为发展中国家的代表,通过介绍药品专利强制许可制度在主要发展中国家的发展和实践,反思我国药品专利强制许可制度的现状,并为解决相关问题提出法律和政策思路,以期未来中国能真正建立起符合国情的药品专利强制许可制度。The case of Lu Yong, who purchased anti-cancer drugs as an agent has attracted extensive attention. It is not only a case which violates the criminal law but also a case which reveals the necessity and significance for developing countries to enforce their compulsory licensing of drugs. Based on a detailed case study of India which is a typical developing country, this article studies the practice and development of compulsory licensing system in developing countries, reflecting on the present conditions of this system in China, aiming to come up with relative laws and policies to help China find its compulsory listening system on pharmaceutical patent, which is consistent with China＇s current national circumstances.

关 键 词：药品专利强制许可 印度专利法 申请主体 公众利益 

分 类 号：D923.42[政治法律—民商法学]